Abstract 17764: Ventricular Arrhythmias Requiring Ablation Procedures Are Associated With Lowered Survival Among Patients With Structural Heart Disease
Background: The impact of ablation of Ventricular arrhythmias (VA) on outcomes in patients with structural heart disease (SHD) is unknown.
Methods: A single center, retrospective analysis was performed of a prospectively collected database of patients with SHD undergoing ablation for VA between 2010 and 2015.Their survival was compared to that of an age and sex matched control group, derived from the population of Minnesota between 2010 and 2015(control group 1). It was also compared to a second group, which included consecutive patients with SHD, matched for age, etiology and ejection fraction, who underwent de novo implantable cardioverter defibrillator (ICD) implantation between 2010 and 2015.(control group 2). Survival was identified using national database sources. Kaplan Meier regression analysis was used to compare the survival between groups and the log-rank test was used to evaluate the differences in mortality between the cases and the controls.
Results: The baseline characteristics of the study cohort are documented in Table 1.Mean duration of follow-up was 1.5 ± 1.5 years. The mean age of subjects in control group 2 was 65 ± 11.3 years; 77.2% were males and 64.3% had ischemic cardiomyopathy.Figure 1 depicts survival outcomes among cases and both control groups at 5 years.
Conclusions: VA requiring ablations are associated with increased mortality among patients with SHD. The mortality does not appear to be procedural in etiology, and therefore one must question whether the natural progression of disease is ultimately affected by successful VT catheter ablation. Large clinical trials are required to understand whether these interventions improve mortality.
Author Disclosures: D. Padmanabhan: None. A. Killu: None. S. Kapa: None. T. Munger: None. A. Deshmukh: None. C. Mcleod: None. P. Noseworthy: None. P. Brady: None. M. Madhavan: None. S.J. Asirvatham: Honoraria; Modest; Abiomed, Atricure, Biotronik, Biosense Webster, Boston Scientific, Medtronic, Medintelligence, St Jude, Sanofi-Aventis, Wolters-Kluver, Elsevier, Zoll. P. Friedman: Research Grant; Modest; St Jude medical. Consultant/Advisory Board; Modest; Medtronic, Leadex, Boston Scientific. Other; Modest; Aegis medical, NeoChord, Preventice, Sorin. D.L. Packer: Research Grant; Significant; American Heart Association Foundation Award, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic CryoCath LP, NIH, St. Jude Medical, Siemens, Thermedical. Honoraria; Significant; Abbott Laboratories/Topera, Aperture Diagnostics $0, Biosense Webster $0, Boston Scientific $0, CardioFocus $0, CardioInsight $0, Johnson & Johnson Healthcare Systems $0, Johnson & Johnson $0, MediaSphere Medical, , Medtronic CryoCath $0, Siemens $0, St. Jude Medical $0, Topera. Other; Significant; Royalties: St. Jude Medical, Royalties: Analyze-AVW technology, Royalties: Wiley and Sons. Y. Cha: None. D. Hodge: None. S. Mulpuru: None.
- © 2016 by American Heart Association, Inc.